ClinicalTrials.gg
Active, not recruitingNCT07728396Updated Nov 16, 2026

A Phase 1 Study to Evaluate the Safety and Immunogenicity of GC4006A in Healthy Adults

A Phase 1 interventional study of GC4006A and Normal Saline in COVID - 19, sponsored by GC Biopharma Corp. Active, not recruiting at 1 site in South Korea. Open to participants aged 19 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by GC Biopharma Corp · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jan 2026, registered Jul 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
19 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 90 studies in COVID-19 with a site in Korea, Republic of — 11 open to participants now, 19 under way, 6 of them phase 3. COVID-19 · Korea, Republic of.

Enrollment
45th of 72
72 · median 253
Started
2026
with 3 others
Phase 1
14 of 90
1 open now
Primary completion
2027-05
later than 9 of 18 live
Registered
88th of 90
by date

Among the 90 studies in COVID-19 with a site in Korea, Republic of, this one is the 45th largest by enrollment of the 72 interventional ones that give a count, is one of 4 that started in 2026, is one of 14 in phase 1, reaches primary completion later than 9 of the 18 other live ones, and was the 88th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

11 of the 90 studies in COVID-19 with a site in Korea, Republic of are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 355 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 90 take children under 18; 134 take healthy volunteers.

This study: 19 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in COVID-19 with a site in Korea, Republic of, or all of them as a file.
02

Study summary

A Phase 1, Randomized, Double-blind, Dose-Escalation, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Preventive Vaccine 'GC4006A' in Healthy Adults Aged 19 to 64 Years

03

Conditions studied

  • COVID - 19

Browse trials for

04

Who can participate

Ages eligible
19 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 19-64 with written
  • ≥16 weeks since last COVID-19 vaccination

Exclusion criteria

Exclusion Criteria:

  • Positive SARS-CoV-2 test (RT-PCR/Rapid Antigen) at screening or randomization
  • \<16 weeks since COVID-19 diagnosis
  • History of serious adverse event, allergy, or to the vaccines
  • Pregnant or lactating women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    GC4006A (dose A)

    Biological: GC4006A

  • Experimental
    GC4006A (dose B)

    Biological: GC4006A

  • Experimental
    GC4006A (Dose C)

    Biological: GC4006A

  • Placebo comparator
    Normal Saline

    Participants receive a single dose of placebo matching the volume of the active drug in their assigned cohort.

    Drug: Normal Saline

Interventions

  • BiologicalGC4006A

    administered as a single dose via Intramuscular injection.

  • DrugNormal Saline

    Matching placebo administered as a single dose via Intramuscular injection.

06

What researchers measure

Primary outcomes

  1. Solicited local and systemic AEs

    Time frame: From baseline up to 7 days

  2. Acute adverse events

    Time frame: From baseline up to 30 minutes

  3. Unsolicited adverse AEs

    Time frame: From baseline up to 28 days

Secondary outcomes

  1. Serious adverse events (SAE), Adverse events of special interest (AESI), Medically Attended Adverse Events (MAAE)

    Time frame: From baseline up to week 52

  2. Clinically significant findings in vital signs, laboratory tests, 12-lead electrocardiograms, and physical examinations

    Time frame: From baseline up to week 52

  3. 6. Immunogenicity response (SRR, GMT, GMFR for neutralizing antibodies; SRR, GMC, GMFR for binding antibodies)

    SRR (Seroresponse rate), GMT (Geometric mean titer), GMFR (Geometric mean fold rise), GMC (Geometric mean concentration)

    Time frame: From baseline up to week 52

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for May 2027, 16 months after the start.

Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's planned 16 months is above that.

Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2026
First posted
Jul 27, 2026
StartActual
Jan 28, 2026
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07728396
Lead sponsor
GC Biopharma Corp
Responsible party
Sponsor
First posted
Jul 27, 2026
Start date
Jan 28, 2026
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Nov 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion